Thymalin is a polypeptide complex isolated from calf thymus glands, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It has been used clinically in Russia since the 1980s for immunodeficiency states and as an anti-aging intervention. A landmark 6-year study by Khavinson et al. (2003) showed thymalin + epithalamin treatment reduced mortality by 4.1x in elderly patients compared to controls. Thymalin is proposed to restore thymic function and T-cell immunity that declines with age.
1 independent Janoshik purity test cover Thymalin across 1 vendor.
Category: Immune / Anti-Aging. Evidence rating: C (early/mixed human evidence).
Clinical status: Approved medication in Russia for immunodeficiency. Used clinically since 1982. Western clinical evidence is limited.
Thymalin contains short bioregulatory peptides (primarily di- and tripeptides including Glu-Trp) derived from thymic tissue. These peptides are proposed to interact with DNA regulatory sequences, modulating gene expression related to immune function. Specifically, thymalin is thought to promote…
Research base: 0 registered clinical trials and 5 indexed publications reference Thymalin.
Safety considerations: Well-tolerated in Russian clinical practice over 40+ years; Rare: mild injection site reactions, transient low-grade fever; No serious adverse events reported in published literature.
Reviewed by the PeptideAtlas Editorial Team.
| Half-life | ~30-60 minutes (short peptide complex) |
|---|---|
| Bioavailability | ~100% IM/SC |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Available as research peptide. |
| Vendor | Best tested purity |
|---|---|
| Peptide Crafters | 99.8% |
Related peptides: Vilon.
Vladimir Khavinson developed a theory that short peptides (2-4 amino acids) derived from specific organs can regulate gene expression in those organs by binding complementary DNA sequences. Thymalin (thymus), Epithalon (pineal), Cortagen (brain), and others form a family of organ-specific bioregulators.
The Khavinson 2003 study showed dramatic results (4.1x mortality reduction), but it has limitations including single-center design, potential selection bias, and lack of independent Western replication. The results are remarkable if true but should be interpreted cautiously.
Thymalin is a complex polypeptide extract from calf thymus containing multiple short peptides, while thymosin alpha-1 (Zadaxin) is a single defined 28-amino-acid peptide. Thymosin alpha-1 has stronger clinical evidence including FDA orphan drug designation, Phase III trials in hepatitis B and C, and approved use in over 30 countries. Thymalin is approved only in Russia with evidence published…
The original thymalin preparation is administered by intramuscular injection. However, Khavinson researchers suggest the active dipeptide components (like Glu-Trp/Vilon) may retain some activity when taken sublingually. Oral administration would likely result in significant degradation by gastric and intestinal peptidases. The injectable route remains the established method in Russian clinical…
Vendors with independent lab tests for it: Peptide Crafters.